NSCLC Stage IIIB, NSCLC Stage IV
Conditions
Keywords
NSCLC, EGFR-TKI
Brief summary
This study will treat patients with advanced NSCLC who have already received at least one course of specific anti-cancer treatment but the tumour has started to re-grow following that treatment. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment, it will measure the levels of drug in the body, it will also measure the anti-cancer activity. By using these pieces of information together the best dose of this drug to use in further clinical trials will be selected.
Detailed description
Phase I dose escalation study
Interventions
DRUGSPH1188-11
qd.po
Sponsors
Shanghai Pharmaceuticals Holding Co., Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. 18-70years old, male or female. 2. Histological or cytological confirmation diagnosis of Non Small Cell Lung Cancer(NSCLC),Stage IIIBorIV, previous treatment with 1st EGFR-TKI, and/or previous chemotherapy. Regardless of EGFR mutation status. 3. At least one measurable disease according to RECIST 1.1. 4. Life expectancy of at least 3 months. 5. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1. 6. Females should be using adequate contraceptive measures from the time of screening until 3 months after discontinuing study treatment, should not be breast feeding and must have a negative pregnancy test 7days prior to start of dosing. Males should be willing to use barrier contraception during the trial and 3 months after discontinuing study treatment. 7. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.
Exclusion criteria
1. Treatment with an EGFR-TKI(eg, erlotinib, gefitinib, icotinib) within 7 days or approximately 5x half-life of study entry. 2. Previous treatment with 2nd EGFR-TKI or 3rd EGFR-TKI(eg, afatinib, osimertinib). 3. Any cytotoxic chemotherapy or anticancer drugs within 4 weeks of the first dose of study treatment. 4. Major surgery(excluding placement of vascular access) within 4 weeks of the first dose of study treatment. 5. Radiotherapy within 4 weeks of the first dose of study treatment. 6. Patients currently receiving(or unable to stop use at least 1 week prior to receiving the first dose) medications or herbal supplements known to be potent inhibitors of CYP3A4/CYP2D6, and/or potent inducers of CYP3A4/CYP2D6. 7. Laboratory values within 7 days of the first dose of study treatment: * Absolute neutrophil count\<1.5×10\^9/L * Platelet count \<100×10\^9/L * Haemoglobin\<90 g/L * Alanine aminotransferase\>2.5 times the upper limit of normal(ULN) if no demonstrable liver metastases or \>5 times ULN in the presence of liver metastases. * Aspartate aminotransferase\>2.5 times ULN if no demonstrable liver metastases or \>5 times ULN in the presence of liver metastases. * Total bilirubin\>1.5 times ULN if no liver metastases or \>3 times ULN in the presence of documented Gilbert's Syndrome(unconjugated hyperbilirubinaemia) or liver metastases. * Creatinine\>1.5 times ULN concurrent with creatinine clearance \<50ml/min(measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is\>1.5 times ULN. 8. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events(CTCAE) grade 1 at the time of starting study treatment (except alopecia and prior platinum-therapy related neuropathy) 9. Spinal cord compression or brain metastases unless asymptomatic, stable and not requiring steroids for at least 4 weeks prior to start of study treatment. 10. Any evidence of severe or uncontrolled systemic diseases, including active bleeding, active infection including hepatitis B(HBsAg+ and HBV-DNA+), hepatitis C and human immunodeficiency virus(HIV). 11. Cardiac criteria: QTc\>480msec. LVEF\<50%. Any clinically important abnormalities in rhythm, any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family in first degree relatives or any concomitant medication known to prolong the QT interval. 12. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease. 13. Idiopathic pulmonary fibrosis. 14. Chronic gastrointestinal diseases, characterized by diarrhea. 15. Inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of SPH1188-11. 16. History of Keratitis, ulcerative keratitis, severe xerophthalmia. 17. Previous or concomitant malignancies at other sites, except effectively treated nonmelanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 5 years and is considered to be cured. 18. History of neurological or mental disorders, including epilepsy or dementia. 19. Allergy to the test drug or any excipient of the product. 20. Participate in other drug clinical trials within 4 weeks of the first dose of study treatment. 21. Receiving any other anti-tumor therapy. 22. Women who are breast feeding or pregnant. 23. Judgment by the investigator that the patient should not participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DLT and MTD of SPH1188-11 | 28 days | Incidence and intensity of Adverse Events according to Common Toxicity Criteria (CTC version 4.03) associated with increasing doses of SPH1188-11, to find DLT and MTD |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tmax of SPH1188-11 | 28 days | Evaluate the Tmax of SPH1188-11 |
| ORR of SPH1188-11 | 52 weeks | Objective response rate(ORR) according to RECIST 1.1, ORR=CR+PR |
| PFS of SPH1188-11 | 52 weeks | Progress free survival(PFS) |
| T1/2 of SPH1188-11 | 28 days | Evaluate the T1/2 of SPH1188-11 |
| Cmax of SPH1188-11 | 28 days | Evaluate the Cmax of SPH1188-11 |
| AUC of SPH1188-11 | 28 days | Evaluate the AUC of SPH1188-11 |
| DCR of SPH1188-11 | 52 weeks | Disease control rate(DCR), DCR=CR+PR+SD |
Countries
China
Outcome results
None listed